KLOW Blend is a four-component research formulation containing GHK-Cu, BPC-157, TB-500 and KPV. The component peptides appear in experimental literature examining copper-peptide chemistry, extracellular-matrix signalling, endothelial and cellular pathways, inflammatory signalling and multi-peptide interactions. This article reviews those mechanisms and the published evidence relevant to the individual components for scientific reference.
KLOW combines GHK-Cu, BPC-157, TB-500 and KPV in a fixed formulation. For a component-by-component analysis of the biochemical pathways associated with each peptide, see our KLOW Blend component breakdown.
Quick reference
| Property | Value |
|---|---|
| Blend type | Four-component peptide research formulation |
| Total content | 80 mg per vial |
| GHK-Cu | 50 mg (copper tripeptide) |
| BPC-157 | 10 mg (gastric pentadecapeptide) |
| TB-500 | 10 mg (thymosin beta-4 fragment) |
| KPV | 10 mg (α-MSH C-terminal tripeptide) |
| Form | Blue-tinged lyophilised cake |
| Testing | Third-party HPLC tested — review the applicable COA for the reported analytical scope |
| Storage | 2–8°C refrigerated; −20°C for long-term lyophilised storage; protect from light and moisture |
Why study multiple peptide pathways together?
Multi-component experimental systems can be useful when a research question concerns interactions between distinct signalling pathways rather than the activity of a single molecule in isolation. The KLOW formulation combines four structurally different peptides whose published literature involves copper-peptide chemistry, extracellular-matrix signalling, endothelial pathways, cellular migration and inflammatory signalling.
The combination should not be assumed to reproduce the effects reported for each component individually. Combination-specific evidence is more limited, so experimental interpretation requires appropriate controls and comparison with the individual components.
Component mechanisms
Each component of KLOW has a different molecular structure and a different published research profile. The summaries below describe pathways and experimental endpoints reported for the individual peptides; they should not be read as established properties of the four-component formulation.
GHK-Cu (50mg) — Copper tripeptide
GHK-Cu is a copper-binding tripeptide studied in experimental systems involving copper coordination, extracellular-matrix gene expression, fibroblast biology, oxidative-response pathways and endothelial signalling. Animal and cellular studies have measured endpoints including collagen-associated gene expression, angiogenesis markers and wound-model parameters.
BPC-157 (10mg) — Synthetic pentadecapeptide
BPC-157 is a synthetic 15-amino-acid peptide studied in models involving nitric-oxide-associated signalling, VEGF/VEGFR2 pathways, FAK-paxillin signalling, endothelial responses and gastrointestinal cell or tissue systems. Published evidence is predominantly preclinical.
TB-500 (10mg) — Thymosin beta-4 fragment
TB-500 is a thymosin beta-4-derived peptide used in research on actin-associated cytoskeletal organisation, cellular migration and endothelial signalling. Published studies examine changes in these endpoints rather than establishing a defined effect for the KLOW combination.
KPV (10mg) — α-MSH tripeptide fragment
KPV is a Lys-Pro-Val tripeptide studied in experimental systems involving PepT1-mediated uptake, NF-κB and MAPK signalling and inflammatory mediators. Its research profile is distinct from melanocortin-receptor agonists despite its structural relationship to α-MSH.
Multi-peptide interaction hypotheses
The component literature suggests several areas where signalling pathways may overlap or interact, including endothelial signalling, extracellular-matrix regulation, cellular migration, copper-dependent processes and inflammatory mediators. These are mechanistic hypotheses for experimental investigation rather than established properties of the four-component blend.
Published evidence for the individual peptides is substantially broader than evidence for the complete KLOW formulation. Studies using the blend should therefore distinguish observations about the combined experimental system from conclusions drawn from single-component literature.
Research use only. This article is provided for laboratory and scientific reference purposes. Trutide research products are supplied strictly for in vitro laboratory research and are not for human or veterinary use, clinical use, self-administration, diagnosis, treatment or prevention of disease.
References
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. doi:10.1155/2015/648108
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes. Cosmetics. 2015;2(3):236-247.
- Sikiric P, Seiwerth S, Rucman R, et al. Pentadecapeptide BPC 157 and its effects: a review. Journal of Physiology and Pharmacology. 2018;69(3).
- Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy. 2012;12(1):37-51.
- Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB Journal. 2003;17(14):2103-2105.
- Getting SJ, Christian HC, Flower RJ, Perretti M. Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis and Rheumatism. 2002;46(10):2765-2775.
- Xiao B, Xu Z, Viennois E, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Molecular Therapy. 2017;25(7):1628-1640. doi:10.1016/j.ymthe.2016.11.020
Last updated: 16 May 2026